Posts

Showing posts with the label Medical

Plasma From Covid-19 Survivors Could Be a Lifesaving Treatment

Image
Medical experts discuss the risks and benefits of using donor plasma from Covid-19 survivors—a treatment known as convalescent plasma therapy— to help the very ill recover. Calling all Covid-19 survivors: Health experts believe that if you donate your blood, it might help save the lives of people infected with the coronavirus. If you’ve tested positive for Covid-19, the disease caused by SARS-CoV-2, and you’ve now recovered and are symptom-free, you may be able to help others by donating plasma. This is the liquid part of your blood that contains antibodies that contribute to your immune response. At least that’s the hope pinned on so-called convalescent plasma therapy, according to infectious disease and public health experts. What is convalescent plasma therapy? Convalescent plasma therapy involves taking donated blood from people who have recovered from Covid-19, and spinning it in a centrifuge to separate out the clear watery plasma that contains infection-fighti

Coronavirus vaccine: when will it be ready?

Image
Human trials will begin imminently – but even if they go well and a cure is found, there are many barriers before global immunisation is feasible Even at their most effective – and draconian – containment strategies have only slowed the spread of the respiratory disease Covid-19. With the World Health Organization finally declaring a pandemic, all eyes have turned to the prospect of a vaccine, because only a vaccine can prevent people from getting sick. About 35 companies and academic institutions are racing to create such a vaccine, at least four of which already have candidates they have been testing in animals. The first of these – produced by Boston-based biotech firm Moderna –   will enter human trials imminently . This unprecedented speed is thanks in large part to early Chinese efforts to sequence the genetic material of Sars-CoV-2, the virus that causes Covid-19. China shared that sequence in early January, allowing research groups around the world to grow the li